NeuShen Therapeutics is a biotechnology company focused on developing treatments for central nervous system (CNS) disorders, with operations in Shanghai, China and Boston, MA. The company applies dual research platforms, including AAV-based gene therapy and small-molecule discovery, to advance CNS drug R&D. NeuShen is led by CEO Dr. Joan Shen. In March 2022 the company raised approximately $20M in a Pre-Series A financing. The round was led by Lapam Capital; no other investors were disclosed in the article. NeuShen intends to use the funds to expand its team and catalyze in-house CNS drug discovery efforts in both the US and China.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2022